article thumbnail

Samsung Biologics, GreenLight conclude Covid-19 vaccine engineering run

Pharmaceutical Technology

Samsung Biologics and GreenLight Biosciences have completed the initial commercial-scale engineering run for their messenger ribonucleic acid (mRNA) Covid-19 vaccine under their manufacturing collaboration. The post Samsung Biologics, GreenLight conclude Covid-19 vaccine engineering run appeared first on Pharmaceutical Technology.

Engineer 262
article thumbnail

Precision Biosciences gets grant for engineered meganucleases for modifying human mitochondrial dna

Pharmaceutical Technology

Discover how this mitochondria-targeting engineered meganuclease is revolutionizing genetic research. Unlock the potential of genetic modification with Precision Biosciences Inc's patented MTEM technology for precise editing of eukaryotic cells.

Engineer 195
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

With $100M AstraZeneca deal, a biotech and its investors engineer another buyout

Bio Pharma Dive

An entity originally known as Teneobio has now been the focus of three acquisition deals with large pharmaceutical companies since 2021, capitalizing on the industry’s growing interest in dual-acting antibody drugs.

Engineer 328
article thumbnail

At EpiBiologics, a pair of Genentech alumni wants to make next-gen protein degraders

Bio Pharma Dive

Armed with a $50 million Series A round, the startup is building off of research from a lab run by protein engineering pioneer Jim Wells.

Protein 357
article thumbnail

5 questions facing biotech M&A in 2022

Bio Pharma Dive

Analysts expect that deal engines are ready to start firing again following the recent quiet period. Still, uncertainty remains about how biopharma acquisitions could play out in the coming months.

Engineer 363
article thumbnail

Third Rock-backed startup launches to develop cell therapies for MS, diabetes

Bio Pharma Dive

Led by CEO Samantha Singer, Abata Therapeutics has $95 million to advance its plans to engineer regulatory T cells for treating autoimmune diseases.

Engineer 335
article thumbnail

Engineers design sutures that can deliver drugs or sense inflammation

Medical Xpress

Inspired by sutures developed thousands of years ago, MIT engineers have designed "smart" sutures that can not only hold tissue in place, but also detect inflammation and release drugs.

Engineer 130